All In MedTech

FDA Clearance Tracker · P230013-S001

EVOQUE Transcatheter Tricuspid Delivery System, EVOQUE Dilator Kit, EVOQUE Loading System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 15, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 15, 2024

Approved

Time to decision

18 days

Received Feb 26, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P230013-S001
Device name
EVOQUE Transcatheter Tricuspid Delivery System, EVOQUE Dilator Kit, EVOQUE Loading System
Applicant location
Irvine, CA
Received
Feb 26, 2024
Decided
Mar 15, 2024
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P230013

Device type

Device class
Class III

Every decision under product code NPW

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site located at 12050 Lone Peak Parkway, Draper, UT 84020 as an alternative finished goods manufacturing site for the EVOQUE transcatheter tricuspid delivery system, EVOQUE dilator kit, and EVOQUE loading System

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.